NasdaqCM - Nasdaq Real Time Price USD

Inhibikase Therapeutics, Inc. (IKT)

Compare
2.6100 -0.0300 (-1.14%)
At close: November 4 at 4:00 PM EST
2.6600 +0.05 (+1.92%)
After hours: November 4 at 5:55 PM EST
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
19,005.3370
20,089.7920
18,128.6080
14,766.1400
2,818.4920
Operating Income
-19,005.3370
-20,089.7920
-18,128.6080
-14,766.1400
-2,818.4920
Net Non Operating Interest Income Expense
622.9550
1,060.9090
74.4530
-19.9230
-29.4020
Pretax Income
-18,382.3820
-19,028.8830
-18,054.1550
-14,786.0630
-2,847.8940
Net Income Common Stockholders
-18,382.3820
-19,028.8830
-18,054.1550
-14,786.0630
-2,847.8940
Diluted NI Available to Com Stockholders
-18,382.3820
-19,028.8830
-18,054.1550
-14,786.0630
-2,847.8940
Basic EPS
-3.21
-3.57
-4.28
-4.86
-2.10
Diluted EPS
-3.21
-3.57
-4.28
-4.86
-2.10
Basic Average Shares
5,861.0380
5,333.0960
4,223.0990
3,034.8660
1,368.7630
Diluted Average Shares
5,861.0380
5,333.0960
4,223.0990
3,034.8660
1,368.7630
Total Operating Income as Reported
-19,005.3370
-20,089.7920
-18,128.6080
-14,766.1400
-2,818.4920
Total Expenses
19,005.3370
20,089.7920
18,128.6080
14,766.1400
2,818.4920
Net Income from Continuing & Discontinued Operation
-18,382.3820
-19,028.8830
-18,054.1550
-14,786.0630
-2,847.8940
Normalized Income
-18,382.3820
-19,028.8830
-18,054.1550
-14,786.0630
-2,847.8940
Interest Income
622.9550
1,060.9090
74.4530
--
--
Interest Expense
0.1630
--
--
19.9230
29.4020
Net Interest Income
622.9550
1,060.9090
74.4530
-19.9230
-29.4020
EBIT
-19,005.3370
-20,089.7920
-18,128.6080
-14,766.1400
-2,818.4920
EBITDA
-18,979.0490
-19,912.3940
-18,121.8850
-14,766.1400
-2,818.4920
Reconciled Depreciation
26.2880
177.3980
6.7230
--
--
Net Income from Continuing Operation Net Minority Interest
-18,382.3820
-19,028.8830
-18,054.1550
-14,786.0630
-2,847.8940
Normalized EBITDA
-18,979.0490
-19,912.3940
-18,121.8850
-14,766.1400
-2,818.4920
12/31/2020 - 12/23/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers